Shares in Stratagene have fallen 23.3 percent over the past week, though the reason for the decline is unclear. The company's shares dropped 15.3 percent last Thursday alone — two days after it announced a settlement with Takara Bio related to PCR enzyme blends, and a day before molecular diagnostics partner Focus Diagnostics announced that it was being acquired by Quest Diagnostics (see Briefs).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.